What it does
Retatrutide is an investigational peptide that activates three incretin receptors simultaneously: GLP-1, GIP, and glucagon. The Phase 2 obesity trial reported mean body-weight reductions of approximately 24% at the highest dose at 48 weeks — the largest figure reported for any pharmacologic in this class to date. Phase 3 trials for obesity, Type 2 diabetes, NASH/MASH, knee osteoarthritis-with-obesity, and cardiovascular outcomes are enrolling and have not yet read out.
Dose
- Starting
- 1,000 mcg · once weekly
- Common
- 6,500 mcg · once weekly
- Upper
- 12,000 mcg · once weekly
- When
- MorningTriple agonist; once-weekly. Time-of-day flexible across the week — pick a consistent slot for adherence. Wednesday morning a common community pick to spread any GI side-effects across the workweek.
- How long
- Continuous (no on/off cycling) on / — off
- Site
- subcutaneous
- Food
- any
Need exact volumes? Open the peptide calculator →
⚠ Caution
- Personal or family history of medullary thyroid carcinoma (class warning extrapolated from GLP-1/GIP rodent data)
- Multiple Endocrine Neoplasia syndrome type 2 (class warning)
- Pregnancy and breastfeeding (no human safety data; investigational compound)
- Severe gastroparesis or active GI motility disorders
- Active substance-use issues affecting nutritional intake
- Investigational status: outside of clinical trials, retatrutide is not available through any FDA-approved channel — anything sold as 'retatrutide' through research-chemical vendors is unregulated
Medications & conditions
- Retatrutide with insulin or sulfonylurea — hypoglycemia riskRetatrutide is a triple GIP/GLP-1/glucagon receptor agonist. Concurrent insulin or sulfonylurea use substantially increases hypoglycemia risk; dose reductions of the concurrent agent are typically required. Do not initiate without prescriber supervision.
Will it work for me?
Establish a baseline (2–3 readings over 1–2 weeks before starting), then track at consistent intervals.
- Tier 1 — Human RCTHbA1c↓· repeat at 3 months
- Tier 1 — Human RCTTriglycerides↓· 12–24 weeks
- Tier 1 — Human RCTLiver enzymes (ALT/AST)↓· 12–24 weeks
- Tier 1 — Human RCTApoB↓· 12–24 weeks
- Tier 2 — Human observationalFIB-4 score↓· 24+ weeksCalculated proxy (age + AST + ALT + platelets) for liver fibrosis; no registry slug — free online calculators (MDCalc).
- Tier 2 — Human observationalLiver fat (FibroScan CAP or MRI-PDFF)↓· ~24 weeksGlucagon component drives standout liver-fat reduction (~80% at 24 weeks on 12 mg) not seen with other GLPs. ~$200–300 cash. No registry slug.
- Tier 3 — Animal / in vitroBody weight↓· tracked weekly; Phase 2 magnitude ~24% at 48 weeks on 12 mgLargest weight-loss signal reported in this class to date.
- Tier 3 — Animal / in vitroResting heart rate↑· track at every visitRetatrutide adds +5 to +7 bpm (vs +2 to +3 for tirzepatide); glucagon-related, peaks ~24 weeks. Monitor — this is a safety-relevant signal, not a benefit.
Your stack
Track this peptide in your protocol — dose, schedule, vials on hand, refill projection. Stays in your browser; no account needed.
Add to my stack